GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (XPAR:MRK) » Definitions » Total Liabilities
中文

Merck (XPAR:MRK) Total Liabilities

: €63,310 Mil (As of Dec. 2023)
View and export this data going back to 1946. Start your Free Trial

Merck's Total Liabilities for the quarter that ended in Dec. 2023 was €63,310 Mil.

Merck's quarterly Total Liabilities increased from Jun. 2023 (€60,666.02 Mil) to Sep. 2023 (€61,305.10 Mil) and increased from Sep. 2023 (€61,305.10 Mil) to Dec. 2023 (€63,309.68 Mil).

Merck's annual Total Liabilities declined from Dec. 2021 (€59,681.75 Mil) to Dec. 2022 (€59,568.29 Mil) but then increased from Dec. 2022 (€59,568.29 Mil) to Dec. 2023 (€63,309.68 Mil).


Merck Total Liabilities Historical Data

The historical data trend for Merck's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52,556.40 54,403.25 59,681.75 59,568.29 63,309.68

Merck Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59,568.29 56,872.19 60,666.02 61,305.10 63,309.68

Merck Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Merck's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=23561.398+(30887.311+8062.264
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+798.707+0)
=63,310

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=97820.975-34511.295
=63,310

Merck's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=23561.398+(30887.311+8062.264
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+798.707+0)
=63,310

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=97820.975-34511.295
=63,310

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck Total Liabilities Related Terms

Thank you for viewing the detailed overview of Merck's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (XPAR:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.